CN105506106A - Method and primer for detecting whole exons of FIX gene - Google Patents

Method and primer for detecting whole exons of FIX gene Download PDF

Info

Publication number
CN105506106A
CN105506106A CN201511023610.4A CN201511023610A CN105506106A CN 105506106 A CN105506106 A CN 105506106A CN 201511023610 A CN201511023610 A CN 201511023610A CN 105506106 A CN105506106 A CN 105506106A
Authority
CN
China
Prior art keywords
fix
primer
gene
sequence
sequencing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201511023610.4A
Other languages
Chinese (zh)
Inventor
李文静
林有升
王淑一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HANGZHOU ADICON CLINICAL LABORATORY CENTER Co Ltd
Original Assignee
HANGZHOU ADICON CLINICAL LABORATORY CENTER Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HANGZHOU ADICON CLINICAL LABORATORY CENTER Co Ltd filed Critical HANGZHOU ADICON CLINICAL LABORATORY CENTER Co Ltd
Priority to CN201511023610.4A priority Critical patent/CN105506106A/en
Publication of CN105506106A publication Critical patent/CN105506106A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a method, primer and a kit for detecting whole exons of an FIX gene. Each of the primer and the kit includes seven pairs of forward and reverse primers which are expanded to cover the whole exon sequence of the FIX gene; a pair of universal primers is utilized as sequencing primers for detecting mutation conditions of the whole exon sequence of the FIX gene by virtue of a Sanger sequencing method. The primer and the method can be applied to the aspects of gene diagnosis, family female carrier detection, prenatal gene diagnosis and the like of patients with hemophilia B.

Description

Detect method and the primer of the full exon of FIX gene
Technical field
The invention belongs to life science and biological technical field, particularly detect primer and the method for the full exons mutation of FIX gene
Background technology
Hemophilia B is also referred to as plasma thromboplastin component (FIX) deficiency disease, it is a kind of X-linkage recessive hereditary disease, pathogenesis is that FIX (F9) transgenation causes FIX content in blood plasma to reduce or functional defect, and the sickness rate in the male sex is 1/30000, rare in women.Hemophilia B symptom main manifestations is that each position of entire patient is spontaneous or excessively hemorrhage after damaging, and there is no effective cure method at present, can only be alleviated by blood transfusion or FIX concentrate formulation or be delayed symptom, bring white elephant thus to patient home and society.
FIX gene is positioned at Xq26.3-27.2, total length 34kb, is made up of the tune region in 8 exons, 7 introns and flanking sequence.8 exon length from 25bp to 1935bp not etc., exons 1 coded signal peptide, the protein excretion of bootable synthesis is in blood; Exon 2 and 3 coding propetide and GLA structural domains; Exon 4 is encoded skins somatomedin structural domain I, this structural domain can with Ca 2+combine closely; Exon 5 is encoded skins somatomedin domain II; The encoding activating structural domain of exon 6, in coagulation process, under the acting in conjunction of XIa, VII a and tissue factor, FIX will be cut off at the 221st hyte propylhomoserin, the 269th arginine and the 365th Serine place, form light chain and heavy chain, now FIX is just transformed to activated FIXa; Exon 7 and 8 coding catalyst structure domains, play a very important role in the conversion of FXa at catalysis FX.FIX genetic flaw type is very various, the sudden change FIX transgenation of collecting in up-to-date human mutation database is more than 1000, comprise point mutation, the insertion of small segment and disappearance, large fragment copy the various mutations types such as rearrangement, wherein modal be caused by single base mutation missense mutation, nonsense mutation and splice mutation.
Before gene sequencing technology is not yet universal, family linkage analysis is the method being most commonly used to hemophilia family female carrier detection and prenatal gene diagnosis.Because linkage analysis need provide the blood sample of several member in family, make the genetic information of family complete as far as possible, and could adopt when the significant site with polymorphism meaning must be detected, thus may face many restrictions when reality uses.When the pleomorphism site adopted is positioned at outside gene, also may linkage analysis be made due to homologous recombination phnomena to occur mistake, cause final result to judge to produce larger error.Direct mutagenesis detection to F9 gene direct Sequencing by DNA sequencer, is found out the accurate location of sudden change, can be provided information more accurately.Owing to achieving automated operation, the PCR that we adopt, in conjunction with DNA direct Sequencing method, thus substantially reduces Diagnostic Time, the man power and material saved, and order-checking efficiency is high, and can determine position and the form of transgenation, result is also more clear and definite.
Several genes mutation detection techniques comprises the methods such as protein truncation test (PTT), single strand conformation polymorphism (SSCP), heteroduple analysis (HA), denaturing gradient gel electrophoresis (DGGE) and temperature gradient gel elec-trophoresis (TGGE) (TGGE), but all these methods all have certain limitation, thus limit the recall rate of transgenation.The method of detection in Gene Mutation conventional is at present gene sequencing and quantitative fluorescent PCR etc.Because FIX capacity is large, mutation type is many, mutation rate is high, mutational site is dispersed in distribution, so prevent the further investigation to FIX transgenation, fluorescence quantitative PCR method is also inapplicable.
Summary of the invention
The invention provides the primer detecting the full exon of FIX gene, adopt Sanger sequencing, can be used for the situation of the full exons mutation of rapid detection FIX gene, for the gene diagnosis of HB.
The object of the present invention is to provide the primer detecting the full exon of FIX gene, comprising: 7 of the full exons mutation of amplification covering detection FIX gene aligns, reverse primer; Its base sequence is:
FIX-1-F:TGTAAAACGACGGCCAGTGTACAACTAATCGACCTTACCACTT
FIX-1-R:AACAGCTATGACCATGCGTGCTGGCTGTTAGACTCT
FIX-2+3-F:TGTAAAACGACGGCCAGTCCCTAAAGAGAAATTGGCTTTCAG
FIX-2+3-R:AACAGCTATGACCATGGAATTGCTTACCAACATACTGCTTC
FIX-4F:TGTAAAACGACGGCCAGTTGGCTTCCAGGTCAGTAGTT
FIX-4R:AACAGCTATGACCATGAGGTGAGTCGGAACATCATTATTAC
FIX-5F:TGTAAAACGACGGCCAGTCACTCTTATTTCAAGGCTCCAA
FIX-5R:AACAGCTATGACCATGAAGGAAGCAGATTCAAGTAGGA
FIX-6F:TGTAAAACGACGGCCAGTGCTTGAGACTCTATTCACTGATTAG
FIX-6R:AACAGCTATGACCATGCATCCCAATAGGTCTGTCTAGTA
FIX-7F:TGTAAAACGACGGCCAGTGCCAGCACCTAGAAGCCAATA
FIX-7R:AACAGCTATGACCATGCCCTTCTGCCTTTAGCCCAAT
FIX-8F:TGTAAAACGACGGCCAGTGGTGAACATAATATTGAGGAGACAG
FIX-8R:AACAGCTATGACCATGTTAGTTAGTGAGAGGCCCTGTTAA
Further, described 7 to align, the working concentration ratio of reverse primer is: FIX-1F:FIX-1R=1:1; FIX-2+3F:FIX-2+3R=1:1; FIX-4F:FIX-4R=1:1; FIX-5F:FIX-5R=1:1; FIX-6F:FIX-6R=1:1; FIX-7F:FIX-7R=1:1; FIX-8F:FIX-8R=1:1.
The present invention also aims to provide a kind of method detecting the full exon of FIX gene, it comprises the steps:
(1) sample DNA is extracted;
(2) 7 couples of amplimer FIX-1F and FIX-1R are utilized; FIX-2+3F and FIX-2+3R; FIX-4F and FIX-4R; FIX-5F and FIX-5R; FIX-6F and FIX-6R; FIX-7F and FIX-7R; FIX-8F and FIX-8R increases to the DNA in (1), obtains the amplified production covering and detect the full exon sequence of FIX gene;
(3) utilize 1 couple of sequencing primer M13-F and M13-R to carry out forward and backward sequencing to the amplified production in (2), obtain the gene order of described amplified production;
(4) gene order in (3) and wild-type FIX gene order are compared, determine whether mutational site exists; Wherein said primer sequence is:
FIX-1-F:TGTAAAACGACGGCCAGTGTACAACTAATCGACCTTACCACTT
FIX-1-R:AACAGCTATGACCATGCGTGCTGGCTGTTAGACTCT
FIX-2+3-F:TGTAAAACGACGGCCAGTCCCTAAAGAGAAATTGGCTTTCAG
FIX-2+3-R:AACAGCTATGACCATGGAATTGCTTACCAACATACTGCTTC
FIX-4F:TGTAAAACGACGGCCAGTTGGCTTCCAGGTCAGTAGTT
FIX-4R:AACAGCTATGACCATGAGGTGAGTCGGAACATCATTATTAC
FIX-5F:TGTAAAACGACGGCCAGTCACTCTTATTTCAAGGCTCCAA
FIX-5R:AACAGCTATGACCATGAAGGAAGCAGATTCAAGTAGGA
FIX-6F:TGTAAAACGACGGCCAGTGCTTGAGACTCTATTCACTGATTAG
FIX-6R:AACAGCTATGACCATGCATCCCAATAGGTCTGTCTAGTA
FIX-7F:TGTAAAACGACGGCCAGTGCCAGCACCTAGAAGCCAATA
FIX-7R:AACAGCTATGACCATGCCCTTCTGCCTTTAGCCCAAT
FIX-8F:TGTAAAACGACGGCCAGTGGTGAACATAATATTGAGGAGACAG
FIX-8R:AACAGCTATGACCATGTTAGTTAGTGAGAGGCCCTGTTAA
M13-F:TGTAAAACGACGGCCAGT
M13-R:AACAGCTATGACCATG
The present invention also aims to provide a kind of test kit detecting the full exon of FIX gene, described test kit comprises sample DNA extraction agent; Dehydrated alcohol; Detection system PCR reaction solution, order-checking system reaction solution, positive reference substance, negative controls and blank product, wherein detection system PCR reaction solution comprises 7 couples of amplimer FIX-1F and FIX-1R; FIX-2+3F and FIX-2+3R; FIX-4F and FIX-4R; FIX-5F and FIX-5R; FIX-6F and FIX-6R; FIX-7F and FIX-7R; FIX-8F and FIX-8R, order-checking system comprises 1 couple of sequencing primer M13-F and M13-R, comprising:
FIX-1-F:TGTAAAACGACGGCCAGTGTACAACTAATCGACCTTACCACTT
FIX-1-R:AACAGCTATGACCATGCGTGCTGGCTGTTAGACTCT
FIX-2+3-F:TGTAAAACGACGGCCAGTCCCTAAAGAGAAATTGGCTTTCAG
FIX-2+3-R:AACAGCTATGACCATGGAATTGCTTACCAACATACTGCTTC
FIX-4F:TGTAAAACGACGGCCAGTTGGCTTCCAGGTCAGTAGTT
FIX-4R:AACAGCTATGACCATGAGGTGAGTCGGAACATCATTATTAC
FIX-5F:TGTAAAACGACGGCCAGTCACTCTTATTTCAAGGCTCCAA
FIX-5R:AACAGCTATGACCATGAAGGAAGCAGATTCAAGTAGGA
FIX-6F:TGTAAAACGACGGCCAGTGCTTGAGACTCTATTCACTGATTAG
FIX-6R:AACAGCTATGACCATGCATCCCAATAGGTCTGTCTAGTA
FIX-7F:TGTAAAACGACGGCCAGTGCCAGCACCTAGAAGCCAATA
FIX-7R:AACAGCTATGACCATGCCCTTCTGCCTTTAGCCCAAT
FIX-8F:TGTAAAACGACGGCCAGTGGTGAACATAATATTGAGGAGACAG
FIX-8R:AACAGCTATGACCATGTTAGTTAGTGAGAGGCCCTGTTAA
M13-F:TGTAAAACGACGGCCAGT
M13-R:AACAGCTATGACCATG
Further, described detection system PCR reaction solution also comprises 2 × PCRBuffer; DNTPs; KODFXDNAPolymerase.
Further, described order-checking system also comprises order-checking refined solution, EDTA, dehydrated alcohol, 75% ethanol, HIDI and BigdyeTerminatorV3.1.
Further, described order-checking refined solution comprises shrimp alkaline phosphotase and exonuclease I.
The present invention devises amplification and covers and detect that 7 of FIX gene full exon sequence aligns, reverse primer, and the upstream primer 5 ' at pcr amplification of novelty end and downstream primer 5 ' are held and added the M13-F primer sequence of a segment length 18bp and the M13-R primer sequence of long 16bp respectively.Introduced M13-F and M13-R primer sequence all can be brought in such amplified production two ends, and when carrying out sequencing reaction subsequently, all amplified productions can use unified M13-F and M13-R primer to carry out forward and reverse order-checking.Because FIX gene has 8 exons, each pattern detection needs amplification 7 PCR primer, if each product uses respective sequencing primer to check order, operation will be very loaded down with trivial details, also very easily causes pollution.And the such design of this test kit effectively avoids this problem, enormously simplify the operation steps of sequencing reaction, makes whole process very convenient.Simultaneously by the reaction conditions such as concentration, annealing temperature of the forward and reverse primer of adjustment, amplification efficiency can be made to reach best.
Utilize expansion primer of the present invention and sequencing primer, Sanger sequencing is adopted to detect the sudden change of the full exon sequence of FIX gene, whole full exon sequence can be expanded, by the analysis of sequencing result, the transgenation situation of the full exon of FIX gene can be got information about very much, not by FIX sudden change variation and the impact not having mutantional hotspot, all mutational sites to be detected can be covered, and save testing cost significantly; There is very high specificity and accuracy; Adopt PCR method amplifying target genes and its gene pleiomorphism of order-checking detection, have highly sensitive, simple to operate, low cost and other advantages.
Accompanying drawing explanation
The detected result figure of Fig. 1 sample 1.
The detected result figure of Fig. 2 sample 2.
The detected result figure of Fig. 3 sample 3.
The detected result figure of Fig. 4 sample 4.
The detected result figure of Fig. 5 sample 5.
The detected result figure of Fig. 6 sample 6.
The detected result figure of Fig. 7 sample 7.
Embodiment
Below in conjunction with specific embodiments and the drawings, set forth the present invention further.Should be noted that, unaccounted normal condition and method in embodiment, usually according to the conventional employing method of affiliated field experimenter: such as, " the fine works molecular biology experiment guide " the 4th edition of Ao Sibai and James Kingston chief editor, or the step of advising according to manufacturer and condition.
Embodiment 1
Detect the primer of the full exon of FIX gene, comprising: 7 of the full exon of amplification covering detection FIX gene aligns, reverse primer; The base sequence of described expansion primer is:
FIX-1-F:TGTAAAACGACGGCCAGTGTACAACTAATCGACCTTACCACTT
FIX-1-R:AACAGCTATGACCATGCGTGCTGGCTGTTAGACTCT
FIX-2+3-F:TGTAAAACGACGGCCAGTCCCTAAAGAGAAATTGGCTTTCAG
FIX-2+3-R:AACAGCTATGACCATGGAATTGCTTACCAACATACTGCTTC
FIX-4F:TGTAAAACGACGGCCAGTTGGCTTCCAGGTCAGTAGTT
FIX-4R:AACAGCTATGACCATGAGGTGAGTCGGAACATCATTATTAC
FIX-5F:TGTAAAACGACGGCCAGTCACTCTTATTTCAAGGCTCCAA
FIX-5R:AACAGCTATGACCATGAAGGAAGCAGATTCAAGTAGGA
FIX-6F:TGTAAAACGACGGCCAGTGCTTGAGACTCTATTCACTGATTAG
FIX-6R:AACAGCTATGACCATGCATCCCAATAGGTCTGTCTAGTA
FIX-7F:TGTAAAACGACGGCCAGTGCCAGCACCTAGAAGCCAATA
FIX-7R:AACAGCTATGACCATGCCCTTCTGCCTTTAGCCCAAT
FIX-8F:TGTAAAACGACGGCCAGTGGTGAACATAATATTGAGGAGACAG
FIX-8R:AACAGCTATGACCATGTTAGTTAGTGAGAGGCCCTGTTAA
Described primer also comprises 1 pair of sequencing primer, and its base sequence is
M13-F:TGTAAAACGACGGCCAGT
M13-R:AACAGCTATGACCATG
In the detection, above-mentioned 7 are first utilized to increase to covering the DNA fragmentation detecting the full exon of FIX gene to forward and reverse amplimer, obtain amplified production, then utilize above-mentioned 1 pair of sequencing primer to check order to amplified production, obtain the gene order of amplified production.
In design of primers, often pair of designed primer is all positioned at the exon sequence both sides that will increase, and namely amplification region includes the full sequence of this exon.Because the mutational site of FIX is a lot, mutation type is indefinite.Therefore described whole exon sequence can all increase out by primer of the present invention, also ensures to undergo mutation in the position, where of no matter exon, all there will not be undetected situation.Because the 2nd and 3 exon sequences are all shorter, the position in gene order is 9291-9454,9643-9667 respectively, and middle intron sequences also only has 189bp, and therefore the present invention is when detection the 2nd and 3 exon, adopts with a pair amplimer.
Detect the test kit of the full exon of FIX gene, comprising: tissue DNA extraction agent box (such as using the extraction test kit of sky root biology); Dehydrated alcohol; Detection system PCR reaction solution, order-checking system reaction solution, positive reference substance, negative controls and blank product, wherein
Detection system PCR reaction solution comprises: 2 × PCRBuffer; 2mMdNTPs; KODFXDNAPolymerase (1U/ μ l); 7 couples of upstream and downstream primers F IX-1F (10 μm) and the FIX-1R (10 μm) of testing goal gene; FIX-2+3F (10 μm) and FIX-2+3R (10 μm); FIX-4F (10 μm) and FIX-4R (10 μm); FIX-5F (10 μm) and FIX-5R (10 μm); FIX-6F (10 μm) and FIX-6R (10 μm); FIX-7F (10 μm) and FIX-7R (10 μm); FIX-8F (10 μm) and FIX-8R (10 μm).
Order-checking system comprises: order-checking refined solution, EDTA (125mmol), dehydrated alcohol, 75% ethanol, HIDI (height deionized formamide), sequencing primer: M13-F (3.2 μm) and M13-R (3.2 μm), and BigdyeTerminatorV3.1 (buying from AppliedBiosystems company of the U.S.), the refined solution that wherein checks order comprises shrimp alkaline phosphotase (SAP) 0.6U and exonuclease I (EXONI) 1.2U.
Detection system PCR reaction solution is formulated as follows:
Wherein, FIX-1F and FIX-1R; FIX-2+3F and FIX-2+3R; FIX-4F and FIX-4R; FIX-5F and FIX-5R; FIX-6F and FIX-6R; FIX-7F and FIX-7R; The base sequence of FIX-8F and FIX-8R is:
FIX-1-F:TGTAAAACGACGGCCAGTGTACAACTAATCGACCTTACCACTT
FIX-1-R:AACAGCTATGACCATGCGTGCTGGCTGTTAGACTCT
FIX-2+3-F:TGTAAAACGACGGCCAGTCCCTAAAGAGAAATTGGCTTTCAG
FIX-2+3-R:AACAGCTATGACCATGGAATTGCTTACCAACATACTGCTTC
FIX-4F:TGTAAAACGACGGCCAGTTGGCTTCCAGGTCAGTAGTT
FIX-4R:AACAGCTATGACCATGAGGTGAGTCGGAACATCATTATTAC
FIX-5F:TGTAAAACGACGGCCAGTCACTCTTATTTCAAGGCTCCAA
FIX-5R:AACAGCTATGACCATGAAGGAAGCAGATTCAAGTAGGA
FIX-6F:TGTAAAACGACGGCCAGTGCTTGAGACTCTATTCACTGATTAG
FIX-6R:AACAGCTATGACCATGCATCCCAATAGGTCTGTCTAGTA
FIX-7F:TGTAAAACGACGGCCAGTGCCAGCACCTAGAAGCCAATA
FIX-7R:AACAGCTATGACCATGCCCTTCTGCCTTTAGCCCAAT
FIX-8F:TGTAAAACGACGGCCAGTGGTGAACATAATATTGAGGAGACAG
FIX-8R:AACAGCTATGACCATGTTAGTTAGTGAGAGGCCCTGTTAA
Positive reference substance: the solution containing FIX sequence.
Negative controls: without the solution of FIX sequence.
Blank product: 2 μ l physiological saline or do not add any material.
Embodiment 2
The operating process of blood DNA extraction agent box (sky root is biological):
(1) genomic dna in extracting blood:
1) extract 500uL blood and add 1000uL erythrocyte cracked liquid, put upside down mixing, room temperature places 5 minutes, and period puts upside down mixing several times again.The centrifugal 5min of 3000rpm, sucks supernatant, leaves leukocyte cell pellet, adds 200uL damping fluid GA, and vibration is to thoroughly mixing.
2) 20 μ l Proteinase K Solution are added, mixing.
3) add 200 μ l damping fluid GB, fully put upside down mixing, place 10 minutes for 70 DEG C, solution strain is limpid, and brief centrifugation is to remove the globule of cap wall.
4) add 200 μ l dehydrated alcohols, fully vibration mixing 15 seconds, now may occur flocks, brief centrifugation is to remove the globule of cap wall.
5) all add in an adsorption column CB3 (adsorption column puts into collection tube) by previous step gained solution and flocks, centrifugal 30 seconds of 12,000rpm (13,400 × g), outwells waste liquid, is put back in collection tube by adsorption column CB3.
6) in adsorption column CB3, add 500 μ l damping fluid GD (please first check whether before use and added dehydrated alcohol), centrifugal 30 seconds of 12,000rpm (13,400 × g), outwells waste liquid, adsorption column CB3 is put into collection tube.
7) in adsorption column CB3, add 700 μ l rinsing liquid PW (please first check whether before use and added dehydrated alcohol), centrifugal 30 seconds of 12,000rpm (13,400 × g), outwells waste liquid, adsorption column CB3 is put into collection tube.
8) in adsorption column CB3, add 500 μ l rinsing liquid PW, centrifugal 30 seconds of 12,000rpm (13,400 × g), outwells waste liquid.
9) put back in collection tube by adsorption column CB3, centrifugal 2 minutes of 12,000rpm (13,400 × g), outwells waste liquid.Adsorption column CB3 is placed in room temperature and places several minutes, thoroughly to dry rinsing liquid remaining in sorbing material.
10) proceeded to by adsorption column CB3 in a clean centrifuge tube, the unsettled dropping 100 in the middle part to adsorption film μ l elution buffer TE, room temperature places 2-5 minute, 12, centrifugal 2 minutes of 000rpm (13,400 × g), by solution collection in centrifuge tube.
(2) reagent configuration: by detecting people's number configuration detection system PCR reaction solution each X μ l, every person-portion 18 μ l packing:
X=18 μ l reaction solution × (n part sample+1 part of positive control+1 part of negative control+1 part of blank)
N is for detecting number of samples.
(3) application of sample: add each 2 μ lDNA in 3 detection system PCR reaction solutions; Positive control and negative control directly add 2 μ l positive reference substance and negative controls; Blank adds 2 μ l physiological saline or does not add any material.
(4) increase: detect and carry out on Standard PCR instrument, available instrumentation comprises ABIveriti (AppliedBiosystems company of the U.S.) etc.Reaction conditions is as follows:
(5) sanger order-checking:
Get 9 μ lPCR products and 2 μ l purification system.Purifying is carried out according to following program:
By 1 μ l purified product respectively with sequencing primer: M13-F (3.2 μm) and M13-R (3.2 μm), mix according to following system:
Sequencing reaction program:
Precipitation link:
In the product completing sequencing reaction, add the EDTA of 2 μ l125mmol, leave standstill 5min; Add 15ml dehydrated alcohol, whirlpool mixes; The centrifugal 30min of 3700rpm; Be inverted centrifugal 15sec, add 50ml70% ethanol, whirlpool mixes; The centrifugal 15min of 3700rpm; Be inverted centrifugal 15sec, be placed on 95 DEG C of metal baths; Denatured test is carried out after adding 10 μ lHIDI.Denaturation program:
After denaturation program terminates, upper sequenator (ABI3730) checks order.
(7) result judges: sequencing result and wild-type reference sequence (GeneBankNo.:K02402.1) are compared, report according to actual catastrophe to result.
Embodiment 3
Get 7 parts, clinical patients sample, whether 7 increments are originally all uncertain suffers from HB, detects this 7 increment and originally whether there is FIX sudden change.Genome, reagent preparation detecting is extracted by method described in embodiment 2.Every increment product add 2 μ l in detection system PCR reaction solution.Do the positive simultaneously, negative, each portion of blank.Detect with regular-PCR instrument, the time is 160 minutes.
The part forward sequencing result of No. 1 full exon sequence of sample 1 as shown in Figure 1, is wild-type, does not detect that FIX suddenlys change.
No. 2 of sample 2 and the part forward sequencing result of No. 3 full exon sequences as shown in Figure 1, are wild-type, do not detect that FIX suddenlys change.
The part forward sequencing result of No. 4 full exon sequence of sample 3 as shown in Figure 1, is wild-type, does not detect that FIX suddenlys change.
The part forward sequencing result of No. 5 full exon sequence of sample 4 as shown in Figure 1, is wild-type, does not detect that FIX suddenlys change.
The part forward sequencing result of No. 6 full exon sequence of sample 5 as shown in Figure 1, is wild-type, does not detect that FIX suddenlys change.
The part forward sequencing result of No. 7 full exon sequence of sample 6 as shown in Figure 1, is wild-type, does not detect that FIX suddenlys change.
The part forward sequencing result of No. 8 full exon sequence of sample 7 as shown in Figure 1, is wild-type, does not detect that FIX suddenlys change.
As can be seen from detected result, primer of the present invention has been included exon sequence, can expand the full exon of FIX gene, and sequencing result entirely accurate.Primer of the present invention can expand the full exon sequence of FIX gene accurately, no matter is wild-type or saltant type.

Claims (3)

1. detect the primer of the full exon of FIX gene, it is characterized in that, comprising: amplification covers the forward and reverse primer detecting the full exon of FIX gene; Its base sequence is:
FIX-1-F:TGTAAAACGACGGCCAGTGTACAACTAATCGACCTTACCACTT
FIX-1-R:AACAGCTATGACCATGCGTGCTGGCTGTTAGACTCT
FIX-2+3-F:TGTAAAACGACGGCCAGTCCCTAAAGAGAAATTGGCTTTCAG
FIX-2+3-R:AACAGCTATGACCATGGAATTGCTTACCAACATACTGCTTC
FIX-4F:TGTAAAACGACGGCCAGTTGGCTTCCAGGTCAGTAGTT
FIX-4R:AACAGCTATGACCATGAGGTGAGTCGGAACATCATTATTAC
FIX-5F:TGTAAAACGACGGCCAGTCACTCTTATTTCAAGGCTCCAA
FIX-5R:AACAGCTATGACCATGAAGGAAGCAGATTCAAGTAGGA
FIX-6F:TGTAAAACGACGGCCAGTGCTTGAGACTCTATTCACTGATTAG
FIX-6R:AACAGCTATGACCATGCATCCCAATAGGTCTGTCTAGTA
FIX-7F:TGTAAAACGACGGCCAGTGCCAGCACCTAGAAGCCAATA
FIX-7R:AACAGCTATGACCATGCCCTTCTGCCTTTAGCCCAAT
FIX-8F:TGTAAAACGACGGCCAGTGGTGAACATAATATTGAGGAGACAG
FIX-8R:AACAGCTATGACCATGTTAGTTAGTGAGAGGCCCTGTTAA。
2. the primer as described in one of claim 1 to 2, is characterized in that, described 7 to align, the working concentration ratio of reverse primer is: FIX-1F:FIX-1R=1:1; FIX-2+3F:FIX-2+3R=1:1; FIX-4F:FIX-4R=1:1; FIX-5F:FIX-5R=1:1; FIX-6F:FIX-6R=1:1; FIX-7F:FIX-7R=1:1; FIX-8F:FIX-8R=1:1.
3. detect a method for the full exon sequence of FIX gene, it comprises the steps:
(1) sample DNA is extracted;
(2) 7 couples of amplimer FIX-1F and FIX-1R are utilized; FIX-2+3F and FIX-2+3R; FIX-4F and FIX-4R; FIX-5F and FIX-5R; FIX-6F and FIX-6R; FIX-7F and FIX-7R; FIX-8F and FIX-8R.DNA in (1) is increased respectively, obtains the amplified production covering and detect the full exon of FIX gene;
(3) utilize 1 couple of sequencing primer M13-F and M13-R to carry out forward and backward sequencing respectively to the amplified production in (2), obtain the gene order of described amplified production;
(4) gene order in (3) and wild-type FIX sequence are compared, determine whether mutational site exists;
Wherein said primer sequence is:
FIX-1-F:TGTAAAACGACGGCCAGTGTACAACTAATCGACCTTACCACTT
FIX-1-R:AACAGCTATGACCATGCGTGCTGGCTGTTAGACTCT
FIX-2+3-F:TGTAAAACGACGGCCAGTCCCTAAAGAGAAATTGGCTTTCAG
FIX-2+3-R:AACAGCTATGACCATGGAATTGCTTACCAACATACTGCTTC
FIX-4F:TGTAAAACGACGGCCAGTTGGCTTCCAGGTCAGTAGTT
FIX-4R:AACAGCTATGACCATGAGGTGAGTCGGAACATCATTATTAC
FIX-5F:TGTAAAACGACGGCCAGTCACTCTTATTTCAAGGCTCCAA
FIX-5R:AACAGCTATGACCATGAAGGAAGCAGATTCAAGTAGGA
FIX-6F:TGTAAAACGACGGCCAGTGCTTGAGACTCTATTCACTGATTAG
FIX-6R:AACAGCTATGACCATGCATCCCAATAGGTCTGTCTAGTA
FIX-7F:TGTAAAACGACGGCCAGTGCCAGCACCTAGAAGCCAATA
FIX-7R:AACAGCTATGACCATGCCCTTCTGCCTTTAGCCCAAT
FIX-8F:TGTAAAACGACGGCCAGTGGTGAACATAATATTGAGGAGACAG
FIX-8R:AACAGCTATGACCATGTTAGTTAGTGAGAGGCCCTGTTAA
M13-F:TGTAAAACGACGGCCAGT
M13-R:AACAGCTATGACCATG。
CN201511023610.4A 2015-12-30 2015-12-30 Method and primer for detecting whole exons of FIX gene Pending CN105506106A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201511023610.4A CN105506106A (en) 2015-12-30 2015-12-30 Method and primer for detecting whole exons of FIX gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511023610.4A CN105506106A (en) 2015-12-30 2015-12-30 Method and primer for detecting whole exons of FIX gene

Publications (1)

Publication Number Publication Date
CN105506106A true CN105506106A (en) 2016-04-20

Family

ID=55714396

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201511023610.4A Pending CN105506106A (en) 2015-12-30 2015-12-30 Method and primer for detecting whole exons of FIX gene

Country Status (1)

Country Link
CN (1) CN105506106A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106520967A (en) * 2016-11-11 2017-03-22 福州艾迪康医学检验所有限公司 Method and primer for detecting hereditary blood coagulation factor XI(F11) genes
CN106868174A (en) * 2017-03-27 2017-06-20 杭州艾迪康医学检验中心有限公司 Detect the kit and method of the full extron of ADAMTS13 genes
CN108315397A (en) * 2018-04-08 2018-07-24 南昌艾迪康医学检验实验室有限公司 Detect method, primer and the kit of SLCO1B1 gene mutations
CN108315406A (en) * 2018-02-10 2018-07-24 陕西医大血友病研究院 The primer of one group of VIII/F of F, Ⅸ gene mutation for detecting haemophiliac and its application
CN108531573A (en) * 2018-04-11 2018-09-14 杭州艾迪康医学检验中心有限公司 Detect primer, kit and the method for methemoglobinemia CYB5R gene mutations
CN109321638A (en) * 2018-09-30 2019-02-12 济南艾迪康医学检验中心有限公司 Detect primer, method and the kit of the 15th exon site mutation of TSC1
CN109402234A (en) * 2018-11-23 2019-03-01 杭州艾迪康医学检验中心有限公司 Detect the primer and method of DMD A827T, 6436 insC site mutation of DMD A5741T and DMD
CN109628563A (en) * 2019-01-02 2019-04-16 南昌艾迪康医学检验实验室有限公司 Detect primer, kit and the method in the mutational site PIGA gene promoter region 4972A > G
CN109777868A (en) * 2019-01-08 2019-05-21 合肥艾迪康医学检验实验室有限公司 A kind of primer and method detecting 2 gene mutation of JAK3 gene intron
CN114381457A (en) * 2022-01-04 2022-04-22 杭州艾迪康医学检验中心有限公司 DNA molecule, oligonucleotide and kit for detecting c.1026+32T > G site mutation of human PTEN gene

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511373A (en) * 2006-06-19 2009-08-19 阿斯克肋匹奥生物制药公司 Modified factor VIII and factor IX genes and vectors for gene therapy
CN102230002A (en) * 2011-06-03 2011-11-02 上海佰真生物科技有限公司 Detection kit of mutation of pathogenic gene for hemophilia and application thereof
CN103270046A (en) * 2010-10-12 2013-08-28 费城儿童医院 Methods and compositions for treating hemophilia B
CN104046699A (en) * 2014-07-08 2014-09-17 上海交通大学医学院附属瑞金医院 F9 gene copy number variation detection kit

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511373A (en) * 2006-06-19 2009-08-19 阿斯克肋匹奥生物制药公司 Modified factor VIII and factor IX genes and vectors for gene therapy
CN103270046A (en) * 2010-10-12 2013-08-28 费城儿童医院 Methods and compositions for treating hemophilia B
CN102230002A (en) * 2011-06-03 2011-11-02 上海佰真生物科技有限公司 Detection kit of mutation of pathogenic gene for hemophilia and application thereof
CN104046699A (en) * 2014-07-08 2014-09-17 上海交通大学医学院附属瑞金医院 F9 gene copy number variation detection kit

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
G.DE GAETANO等: "Aspirin resistance: a revival of platelet aggregation tests?", 《JOURNAL OF THROMBOSIS AND HAEMOSTASIS》 *
G.JAYHARAN等: "Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions", 《HAEMOPHILIA》 *
YOSHITAKE,S等: "Human coagulation factor IX gene, complete cds", 《GENBANK DATABASE》 *
汪清云: "B型血友病FIX基因突变与发病机制研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 *
贺淹才编著: "《基因工程概论》", 30 April 2008, 清华大学出版社 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106520967A (en) * 2016-11-11 2017-03-22 福州艾迪康医学检验所有限公司 Method and primer for detecting hereditary blood coagulation factor XI(F11) genes
CN106868174A (en) * 2017-03-27 2017-06-20 杭州艾迪康医学检验中心有限公司 Detect the kit and method of the full extron of ADAMTS13 genes
CN108315406A (en) * 2018-02-10 2018-07-24 陕西医大血友病研究院 The primer of one group of VIII/F of F, Ⅸ gene mutation for detecting haemophiliac and its application
CN108315406B (en) * 2018-02-10 2021-08-24 陕西医大血友病研究院 Primers for detecting F VIII/F IX gene mutation of hemophilia patient and application thereof
CN108315397A (en) * 2018-04-08 2018-07-24 南昌艾迪康医学检验实验室有限公司 Detect method, primer and the kit of SLCO1B1 gene mutations
CN108531573A (en) * 2018-04-11 2018-09-14 杭州艾迪康医学检验中心有限公司 Detect primer, kit and the method for methemoglobinemia CYB5R gene mutations
CN109321638A (en) * 2018-09-30 2019-02-12 济南艾迪康医学检验中心有限公司 Detect primer, method and the kit of the 15th exon site mutation of TSC1
CN109402234A (en) * 2018-11-23 2019-03-01 杭州艾迪康医学检验中心有限公司 Detect the primer and method of DMD A827T, 6436 insC site mutation of DMD A5741T and DMD
CN109628563A (en) * 2019-01-02 2019-04-16 南昌艾迪康医学检验实验室有限公司 Detect primer, kit and the method in the mutational site PIGA gene promoter region 4972A > G
CN109777868A (en) * 2019-01-08 2019-05-21 合肥艾迪康医学检验实验室有限公司 A kind of primer and method detecting 2 gene mutation of JAK3 gene intron
CN114381457A (en) * 2022-01-04 2022-04-22 杭州艾迪康医学检验中心有限公司 DNA molecule, oligonucleotide and kit for detecting c.1026+32T > G site mutation of human PTEN gene

Similar Documents

Publication Publication Date Title
CN105506106A (en) Method and primer for detecting whole exons of FIX gene
CN105506107A (en) Primers and method for detecting polymorphic hotspot mutation condition of DOCK2 gene
CN104745697B (en) Detect the method and primer of NF1 the 31st No. 34 full extron of gene
CN104830966A (en) Method of direct DNA sequencing for screening hepatolenticular degeneration disease gene mutation site through PCR amplification
CN104862407A (en) Primer and method for detecting EZH2 genes
CN106520967A (en) Method and primer for detecting hereditary blood coagulation factor XI(F11) genes
CN103555826A (en) Primer, method and kit for detecting mutation of MLH1 gene's 12th exon
CN108531575A (en) Detect primer, kit and the method for the full exon sequence mutation of TERC genes
CN110358820A (en) Detect method, primer and the kit of LDLR gene mutation
CN106399567A (en) Primer for detecting WRAP53 gene mutation and application of primer
CN114369657A (en) Multiple PCR detection method and kit for thrombosis-prone gene mutation
CN110358821A (en) Detect primer, kit and the method for glucose 6 phosphate dehydrogenase deficiency G6PD gene mutation
CN112226440B (en) Pathogenic mutation of hereditary primary infertility and detection reagent thereof
CN106086215A (en) The method in detection No. 4 full exon sequence mutational site of dyskeratosis congenita disease NHP2 gene and primer
CN106222287A (en) The method of detection ELA2 gene and primer
CN106868174A (en) Detect the kit and method of the full extron of ADAMTS13 genes
CN105177152A (en) Method and primers for detecting HLA-B*51 allelomorphic gene
CN103421908A (en) Kit used for screening CYP21A2 gene of Chinese population
CN103540659B (en) Detect the method in DNMT3A mutational site, primer and test kit
CN105506110A (en) Method and primer for detecting 8th and 25th whole exons of TEX11 gene
CN105316349A (en) Mycobacterium tuberculosis KatG mutant gene and application thereof
CN108949952A (en) Detect primer, method and kit that ABCG8 introne 4 is mutated
CN107058531A (en) A kind of kit and method for detecting Niemann-Pick disease SMPD1 gene mutations
CN106282343A (en) Detection NOP10 gene the 2nd exon mutational site R34W(C100T) method of series jump and primer
CN106967819A (en) Detect the kit and method of hyper-IgE syndrome STAT3 gene mutations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160420